The Fox Chase Cancer Center invites applicants for tenure-track faculty positions at the level of assistant professor and associate professor in the Cancer Epigenetics Instituteand Cancer Signaling and Epigenetics Program. While outstanding candidates working in all areas of epigenetics are invited to apply, we are particularly soliciting applications from candidates that are interested in the following areas:
The relationship between higher order genome organization and spatial transcriptomics related to cancer development, progression and/or resistance;
The role of modified RNAs and epi-transcriptomics in cancer;
The use of computational and systems analyses for chromatin biology;
The relationship between immune oncology and epigenetics;
The relationship between metabolic pathways and epigenetic control.
Successful applicants will join a highly interactive institution that is committed to bridging basic discovery to clinical application through collaboration. Fox Chase was among the nation's first institutions to receive Comprehensive Cancer Center designation from the NCI in 1974. There are 119 research faculty that generate $63.2 million in funding. The research faculty are surrounded by clinical colleagues that provide care for over 105,000 individuals and support >170 clinical trials, of which >60 are investigator-initiated. Two particular highlights of the center are the superb clinical pipeline that facilitates rapid translation of basic science discoveries into the clinic and the world-class core facilities that are easily accessed.Applicants interested in joining such an environment should have a Ph.D. and/or M.D. degree with an outstanding record of research productivity. The application should contain the following information - a curriculum vitae, a brief (up to two pages) statement of research interests and future goals and a list of three individuals providing letters of recommendation. Please send the application via email to Johnathan Whetstine (Epigenetics@fccc.edu), Director, Cancer Epigenetics Institute, Co-Leader, Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center.
